David Risinger
Stock Analyst at Leerink Partners
(4.45)
# 289
Out of 4,876 analysts
170
Total ratings
65.17%
Success rate
13.39%
Average return
Main Sectors:
Stocks Rated by David Risinger
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Downgrades: Market Perform | $169 → $153 | $152.41 | +0.39% | 4 | May 13, 2025 | |
| VRTX Vertex Pharmaceuticals | Downgrades: Market Perform | $550 → $503 | $441.30 | +13.98% | 4 | May 6, 2025 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $762 → $834 | $521.00 | +60.08% | 8 | Feb 5, 2025 | |
| ABBV AbbVie | Upgrades: Outperform | $206 | $182.31 | +12.99% | 7 | Nov 22, 2024 | |
| BMY Bristol-Myers Squibb Company | Upgrades: Outperform | $55 → $73 | $46.35 | +57.50% | 4 | Nov 12, 2024 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $49 → $69 | $19.80 | +248.48% | 2 | Nov 11, 2024 | |
| TENX Tenax Therapeutics | Initiates: Outperform | $16 | $5.85 | +173.50% | 1 | Oct 24, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Outperform | $44 | $11.08 | +297.11% | 2 | Sep 17, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $106 → $153 | $32.58 | +369.61% | 2 | Sep 3, 2024 | |
| TBPH Theravance Biopharma | Downgrades: Market Perform | $15 → $10 | $11.22 | -10.87% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $28 → $2 | $1.97 | +1.52% | 2 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $47 | $22.47 | +109.17% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $267 → $318 | $277.13 | +14.75% | 4 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $11 | $13.20 | -16.67% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $410 → $458 | $775.45 | -40.94% | 16 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $42 | $52.21 | -19.56% | 3 | Mar 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $81 → $91 | $110.67 | -17.77% | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $49 → $48 | $24.19 | +98.43% | 14 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $10 | $11.39 | -12.20% | 4 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $10 | $29.64 | -66.26% | 2 | Jun 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $9.86 | +275.25% | 2 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $162 → $176 | $106.90 | +64.64% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $16 | $9.01 | +77.58% | 1 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $53 → $45 | $26.54 | +69.56% | 17 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $22 → $35 | $6.46 | +441.80% | 4 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $41 | $14.29 | +186.91% | 5 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $167 → $174 | $156.17 | +11.42% | 9 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $51 | $35.87 | +42.18% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $8 | $16.76 | -52.27% | 19 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $97 → $89 | $79.10 | +12.52% | 8 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $8.13 | -63.10% | 4 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $16 | $28.81 | -44.46% | 9 | Apr 2, 2020 |
Johnson & Johnson
May 13, 2025
Downgrades: Market Perform
Price Target: $169 → $153
Current: $152.41
Upside: +0.39%
Vertex Pharmaceuticals
May 6, 2025
Downgrades: Market Perform
Price Target: $550 → $503
Current: $441.30
Upside: +13.98%
Regeneron Pharmaceuticals
Feb 5, 2025
Upgrades: Outperform
Price Target: $762 → $834
Current: $521.00
Upside: +60.08%
AbbVie
Nov 22, 2024
Upgrades: Outperform
Price Target: $206
Current: $182.31
Upside: +12.99%
Bristol-Myers Squibb Company
Nov 12, 2024
Upgrades: Outperform
Price Target: $55 → $73
Current: $46.35
Upside: +57.50%
Tectonic Therapeutic
Nov 11, 2024
Maintains: Outperform
Price Target: $49 → $69
Current: $19.80
Upside: +248.48%
Tenax Therapeutics
Oct 24, 2024
Initiates: Outperform
Price Target: $16
Current: $5.85
Upside: +173.50%
Oruka Therapeutics
Sep 17, 2024
Initiates: Outperform
Price Target: $44
Current: $11.08
Upside: +297.11%
Vaxcyte
Sep 3, 2024
Maintains: Outperform
Price Target: $106 → $153
Current: $32.58
Upside: +369.61%
Theravance Biopharma
Aug 6, 2024
Downgrades: Market Perform
Price Target: $15 → $10
Current: $11.22
Upside: -10.87%
Jul 9, 2024
Downgrades: Market Perform
Price Target: $28 → $2
Current: $1.97
Upside: +1.52%
Apr 16, 2024
Initiates: Outperform
Price Target: $47
Current: $22.47
Upside: +109.17%
Oct 11, 2023
Upgrades: Outperform
Price Target: $267 → $318
Current: $277.13
Upside: +14.75%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $11
Current: $13.20
Upside: -16.67%
May 1, 2023
Maintains: Outperform
Price Target: $410 → $458
Current: $775.45
Upside: -40.94%
Mar 16, 2023
Downgrades: Market Perform
Price Target: $42
Current: $52.21
Upside: -19.56%
Feb 3, 2023
Maintains: Market Perform
Price Target: $81 → $91
Current: $110.67
Upside: -17.77%
Feb 1, 2023
Maintains: Market Perform
Price Target: $49 → $48
Current: $24.19
Upside: +98.43%
Dec 19, 2022
Maintains: Outperform
Price Target: $8 → $10
Current: $11.39
Upside: -12.20%
Jun 24, 2022
Maintains: Market Perform
Price Target: $7 → $10
Current: $29.64
Upside: -66.26%
Feb 22, 2022
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $9.86
Upside: +275.25%
Apr 1, 2021
Maintains: Equal-Weight
Price Target: $162 → $176
Current: $106.90
Upside: +64.64%
Mar 10, 2021
Maintains: Equal-Weight
Price Target: $18 → $16
Current: $9.01
Upside: +77.58%
Mar 5, 2021
Maintains: Equal-Weight
Price Target: $53 → $45
Current: $26.54
Upside: +69.56%
Feb 26, 2021
Maintains: Equal-Weight
Price Target: $22 → $35
Current: $6.46
Upside: +441.80%
Nov 24, 2020
Maintains: Overweight
Price Target: $31 → $41
Current: $14.29
Upside: +186.91%
Nov 13, 2020
Maintains: Equal-Weight
Price Target: $167 → $174
Current: $156.17
Upside: +11.42%
Jul 13, 2020
Initiates: Equal-Weight
Price Target: $51
Current: $35.87
Upside: +42.18%
Apr 2, 2020
Maintains: Underweight
Price Target: $13 → $8
Current: $16.76
Upside: -52.27%
Apr 2, 2020
Maintains: Overweight
Price Target: $97 → $89
Current: $79.10
Upside: +12.52%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $8.13
Upside: -63.10%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $20 → $16
Current: $28.81
Upside: -44.46%